source
- Daiichi Sankyo writes off $950 million after abandoning ADC manufacturing planDaiichi Sankyo announced it will abandon its planned antibody-drug conjugate (ADC) manufacturing facility. The company said the decision follows a serious over-estimate of third-party demand for AD…
- FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...Endpoints · 4mo ago↗ source